NCT04919226 · Interventional trial
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Overall registry status Active not recruiting
Phase 3
Conditions Neuroendocrine Tumors
Delaware Valley sites
- Fox Chase Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory